- Product Details
Keywords
- (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate
- INCB018424 (phosphate)
- Ruxolitinib phosphate
Quick Details
- ProName: Ruxolitinib phosphate
- CasNo: 1092939-17-7
- Molecular Formula: C17H18N6.H3PO4
- Appearance: white powder
- Application: Ruxolitinib phosphate (INCB018424) is ...
- DeliveryTime: 2 month
- PackAge: fiber can
- Port: shanghai port
- ProductionCapacity: 100 Kilogram/Year
- Purity: 99%
- Storage: shtore at 2-8 ℃
- Transportation: air transport
- LimitNum: 1 Kilogram
- Related Substances: ≤0.1%
- Residue on Ignition: ≤0.1%
- Heavy Metal: ≤20ppm
- Valid Period: 2 years
Superiority
The quality of our products is guaranteed and the price is low!
Details
CAS number :1092939-17-7
English name :Ruxolitinibphosphate
English alias :INC424; INCB018424; INC424phosphate; Ruxotinibphosphate; Rusotinibphosphate; Jakafi(ruxolitinib); IINCB018424phosphate; Ruxolitinib,Phosphate; INCB018424(phosphate); 10-di
CBNumber:CB82509943
Molecular formula :C17H21N6O4P
Molecular weight :404.37
Melting point :186-190°C
Storage condition :Refrigerator
Solubility :DMSO(SlChemicalbookightly),Methanol(Slightly)
Form :Solid
Color :WhitetoOff-White
Ruxolitinibphosphate is a potent JAK1/2 inhibitor with an IC50 of 3.3nM/2.8nM, which is 130 times more selective than JAK3. In vitro studies, Ruxolitinib (INCB018424) effectively and selectively inhibits JAK2V617F-mediated signaling and proliferation. Ruxolitinib inhibited HEL cell growth with an EC50 of 186nM. Ruxolitinib significantly increased apoptosis of the Ba/F3-EpoR-JAK2V617F cell system and inhibited hematopoietic progenitor cell proliferation in samples from patients with primary MPN. In vivo studies of Ruxolitinib (180mg/kg, po) Chemicalbook reduced tumor load in mice inoculated with Jak2V617F-expressing cells without causing anemia or lymphocytopenia. Bioactive RuxolitinibPhosphate(INCB018424,INC424) is a phosphate form of Ruxolitinib. Ruxolitinib is the first clinically available, potent, selective JAK1/2 inhibitor with an IC50 of 3.3nM/2.8nM in cell-free trials. When acting on JAK1, the selectivity of JAK2 is more than 130 times higher than that of JAK3. Ruxolitinib kills tumor cells through toxic mitochondrial autophagy. Ruxolitinib can induce autophagy and enhance apoptosis. Target point